Insulet (PODD) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $488.5M, up 23.2% year-over-year, driven by Omnipod 5 platform expansion, strong U.S. and international demand, and successful launches and integrations in the U.S. and Europe.

• Net income surged to $188.6M ($2.59 per diluted share), aided by a $146.9M non-cash tax benefit from releasing a valuation allowance; adjusted net income was $38.3M ($0.55 per diluted share).

• Strategic decision to discontinue Omnipod GO, incurring a $13.5M charge for related inventory.

• New manufacturing facility in Malaysia began producing sellable product ahead of schedule, supporting global expansion and expected to be accretive to gross margin.

• Full-year guidance for revenue, gross margin, and operating margin was raised, reflecting robust first-half results and continued momentum.

Financial highlights

• Q2 total revenue: $488.5M (+23.2% YoY); Omnipod revenue: $480.4M (+26.3% YoY); U.S. Omnipod: $352.3M (+27.3% YoY); International Omnipod: $128.1M (+23.5% YoY).

• Gross margin reached 67.7%, up 90 bps year-over-year, despite a $13.5M one-time charge that reduced margin by 280 bps.

• Operating margin was 11.2% (up 340 bps YoY); adjusted EBITDA was $90.8M (18.6% of revenue), both exceeding expectations.

• Cash and cash equivalents increased to $821.0M as of June 30, 2024; available credit: $300M.

• Diluted EPS was $2.59 in Q2 2024, up from $0.39 in Q2 2023.

Outlook and guidance

• Full-year 2024 guidance raised: revenue growth expected at 16%-19%, Omnipod growth at 18%-21%, targeting $2B annual revenue at the high end.

• Gross margin expected near the high end of 68%-69% range for 2024; operating margin guidance raised to ~14%.

• Q3 2024 guidance: revenue growth projected at 18%-21%, with Omnipod segments expected to grow 21%-24% globally.

• Drug Delivery revenue expected to decline 40%-50% for the year, projected at $14–18M.

• R&D and SG&A expenses expected to rise in 2024 to support innovation and international expansion.